Epivax info continues to suggest that funding is the major hurtle :
"The vaccine will not come w/o funding"
UPDATE March 23, 2020:
With all proposed collaborations in place, EpiVax is poised to make a great impact on the rapid development of a COVID-19 vaccine. However, the vaccine will not come without funding. The Coalition for Epidemic Preparedness Innovations (CEPI) has called for $2 Billion USD in immediate government funding for the expansion of vaccine candidates brought to clinical trial, and the increase in chances of success.
EpiVax is happy to share that a request for funding has been submitted to MCDC (DOD). We are eager to be a part of the solution and look forward to continuing driving science forward.
UPDATE March 20, 2020:
While we continue to pursue multiple vaccine collaborators, one of our top priorities remains health care workers. EpiVax is developing an epitope based vaccine that could be ready in as little as 6 months. Scientists at EpiVax have a plan in place for carrying out this rapid development:
Many vaccines and treatments continue to be developed and EpiVax is proud to be on the forefront of these efforts. You may find a complete list here
Vaccines
EpiVax and Generex, Approach: Vaccine, Stage: Preclinical
EpiVax and UGA, Approach: Vaccine, Stage: Preclinical
Moderna Therapeutics, Approach: Vaccine, Stage: Phase 1
CanSino Biologics, Approach: Vaccine, Stage: Phase 1
Arcturus Therapeutics, Approach: Vaccine, Stage: Preclinical
BioNTech, Approach: Vaccine, Stage: Preclinical
CureVac, Approach: Vaccine, Stage: Preclinical
GlaxoSmithKline, Approach: Vaccine, Stage: Preclinical
Inovio Pharmaceuticals, Approach: Vaccine, Stage: Preclinical
Johnson & Johnson, Approach: Vaccine, Stage: Preclinical
Pfizer, Approach: Vaccine, Stage: Preclinical
Sanofi, Approach: Vaccine, Stage: Preclinical
Treatment therapies
UPDATE March 19, 2020:
EpiVax is currently working on a COVID-19 vaccine tailored specifically for healthcare workers. In an interview with WPRI 12, Dr. Anne De Groot stated: “They’re the first line of defense against the virus, so we want to give them something that will actually generate what we call ‘immune system body armor.” It remains critical to EpiVax’s mission to develop this vaccine.
One major hurdle: funding.
EpiVax is currently petitioning for $300 million USD in government aid to follow through with the proper safety and efficacy testing needed to make this vaccine available as rapidly as possible.
UPDATE March 18, 2020:
Dr. Anne De Groot speaks with local NBC 10 News‘ Tamara Sacharczyk about EpiVax’s continuing efforts to develop a COVID-19 vaccine. Dr. De Groot outlines the importance of EpiVax’s proprietary computer tools for rapid identification of vaccine candidates. EpiVax maintains hope that with a peptide based vaccine, Phase 1 trials may begin in as little as 5 – 6 months.
"The vaccine will not come w/o funding"
UPDATE March 23, 2020:
With all proposed collaborations in place, EpiVax is poised to make a great impact on the rapid development of a COVID-19 vaccine. However, the vaccine will not come without funding. The Coalition for Epidemic Preparedness Innovations (CEPI) has called for $2 Billion USD in immediate government funding for the expansion of vaccine candidates brought to clinical trial, and the increase in chances of success.
EpiVax is happy to share that a request for funding has been submitted to MCDC (DOD). We are eager to be a part of the solution and look forward to continuing driving science forward.
UPDATE March 20, 2020:
While we continue to pursue multiple vaccine collaborators, one of our top priorities remains health care workers. EpiVax is developing an epitope based vaccine that could be ready in as little as 6 months. Scientists at EpiVax have a plan in place for carrying out this rapid development:
Many vaccines and treatments continue to be developed and EpiVax is proud to be on the forefront of these efforts. You may find a complete list here
Vaccines
EpiVax and Generex, Approach: Vaccine, Stage: Preclinical
EpiVax and UGA, Approach: Vaccine, Stage: Preclinical
Moderna Therapeutics, Approach: Vaccine, Stage: Phase 1
CanSino Biologics, Approach: Vaccine, Stage: Phase 1
Arcturus Therapeutics, Approach: Vaccine, Stage: Preclinical
BioNTech, Approach: Vaccine, Stage: Preclinical
CureVac, Approach: Vaccine, Stage: Preclinical
GlaxoSmithKline, Approach: Vaccine, Stage: Preclinical
Inovio Pharmaceuticals, Approach: Vaccine, Stage: Preclinical
Johnson & Johnson, Approach: Vaccine, Stage: Preclinical
Pfizer, Approach: Vaccine, Stage: Preclinical
Sanofi, Approach: Vaccine, Stage: Preclinical
Treatment therapies
UPDATE March 19, 2020:
EpiVax is currently working on a COVID-19 vaccine tailored specifically for healthcare workers. In an interview with WPRI 12, Dr. Anne De Groot stated: “They’re the first line of defense against the virus, so we want to give them something that will actually generate what we call ‘immune system body armor.” It remains critical to EpiVax’s mission to develop this vaccine.
One major hurdle: funding.
EpiVax is currently petitioning for $300 million USD in government aid to follow through with the proper safety and efficacy testing needed to make this vaccine available as rapidly as possible.
UPDATE March 18, 2020:
Dr. Anne De Groot speaks with local NBC 10 News‘ Tamara Sacharczyk about EpiVax’s continuing efforts to develop a COVID-19 vaccine. Dr. De Groot outlines the importance of EpiVax’s proprietary computer tools for rapid identification of vaccine candidates. EpiVax maintains hope that with a peptide based vaccine, Phase 1 trials may begin in as little as 5 – 6 months.
